Six Month Freedom from Treatment Failure is an Important Endpoint for Acute Graft-Versus-Host Disease Clinical Trials

We studied the ASBMT 6 month (m) freedom from treatment failure (FFTF) as a predictor of survival for patients with acute graft-versus-host disease (aGVHD) requiring treatment. Adult patients undergoing allogeneic hematopoietic cell transplant (HCT) from February 2007 to March 2009 who were enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Sengsayadeth, Salyka, Savani, Bipin N., Jagasia, Madan, Goodman, Stacey, Greer, John P., Chen, Heidi, Chinratanalab, Wichai, Kassim, Adetola A., Engelhardt, Brian G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946331/
https://www.ncbi.nlm.nih.gov/pubmed/24096824
http://dx.doi.org/10.1038/bmt.2013.157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946331/
https://www.ncbi.nlm.nih.gov/pubmed/24096824
http://dx.doi.org/10.1038/bmt.2013.157

Ejemplares similares